These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Methadone and antiretroviral medications, part II. Gourevitch MN; Friedland GH AIDS Clin Care; 1999 May; 11(5):37, 43, 45-6. PubMed ID: 11367102 [TBL] [Abstract][Full Text] [Related]
3. Unsuspected and paradoxical potential for drug interaction by rifampin: things to ponder with antiretroviral therapy. Srinivas NR J Infect Dis; 2009 Mar; 199(5):766-7; author reply 767. PubMed ID: 19210166 [No Abstract] [Full Text] [Related]
4. The ABC's of pharmacokinetics. Anderson PL Posit Aware; 2005; Spec No():4-7, 19. PubMed ID: 15828101 [No Abstract] [Full Text] [Related]
5. The ups and downs of drug levels. Munk B Posit Aware; 2001; 12(3):33-4. PubMed ID: 11686117 [No Abstract] [Full Text] [Related]
6. FDA notifications. FDA grants approval for raltegravir. AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366 [No Abstract] [Full Text] [Related]
7. [Drug interactions in patients infected with the human immunodeficiency virus]. Jiménez-Nácher I; García-Díaz B; Soriano Vázquez V Rev Clin Esp; 1998 Nov; 198(11):765-8. PubMed ID: 9883052 [No Abstract] [Full Text] [Related]
8. Antiretroviral drug resistance in HIV-infected children: implications for long-term treatment. Tudor-Williams G; Green H J HIV Ther; 2007 Dec; 12(4):99-100. PubMed ID: 18578093 [No Abstract] [Full Text] [Related]
9. Drug interactions chart. An abbreviated, at-a-glance guide to HIV drug interactions. Djuricich P; Vázquez E Posit Aware; 2009; 20(2):56-8. PubMed ID: 19280746 [No Abstract] [Full Text] [Related]
10. Drug interactions chart. An abbreviated, at-a-glance guide to HIV drug interactions. Diaz-Linares M; Vázquez E Posit Aware; 2008; 19(1):50-2. PubMed ID: 18546578 [No Abstract] [Full Text] [Related]
11. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy? Chang SY; Lin SW; Hung CC Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849 [No Abstract] [Full Text] [Related]
12. Creating a friendly environment for your HIV medications. The effect of interactions. Zive JL; Learned J Posit Aware; 2005; Spec No():16-21. PubMed ID: 16335474 [No Abstract] [Full Text] [Related]
13. Getting the most out of treatment. Learned J Posit Aware; 2005; Spec No():2. PubMed ID: 16335471 [No Abstract] [Full Text] [Related]
15. Drug-nutrient interactions and HIV. Maurice J Posit Aware; 2002; 13(4):38-9. PubMed ID: 12171042 [No Abstract] [Full Text] [Related]
16. Treatment activists meet with the FDA. Huff B GMHC Treat Issues; 2003 Nov; 17(11):10-1. PubMed ID: 14717107 [No Abstract] [Full Text] [Related]
17. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. Di Biagio A; Rosso R; Siccardi M; D'Avolio A; Bonora S; Viscoli C J Antimicrob Chemother; 2009 Oct; 64(4):874-5. PubMed ID: 19643773 [No Abstract] [Full Text] [Related]
18. Drug interactions. Rosiglitazone and anti-HIV agents. TreatmentUpdate; 2005; 17(4):8. PubMed ID: 17228471 [No Abstract] [Full Text] [Related]
19. Drug interactions chart. An abbreviated at-a-glance guide to HIV drug interactions. Vázquez E Posit Aware; 2007; 18(1):55-6. PubMed ID: 17288034 [No Abstract] [Full Text] [Related]
20. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Koyalta D; Charpentier C; Beassamda J; Rey E; Si-Mohamed A; Djemadji-Oudjeil N; Bélec L Clin Infect Dis; 2009 Jul; 49(1):155-9. PubMed ID: 19480574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]